149 related articles for article (PubMed ID: 20552253)
21. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
24. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
25. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.
Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
27. Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats.
Mas-Fuster MI; Ramon-Lopez A; Lacueva J; Compañ A; Más-Serrano P; Nalda-Molina R
Cancer Chemother Pharmacol; 2017 Mar; 79(3):621-627. PubMed ID: 28168311
[TBL] [Abstract][Full Text] [Related]
28. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
Jacobs S; McCully CL; Murphy RF; Bacher J; Balis FM; Fox E
Cancer Chemother Pharmacol; 2010 Apr; 65(5):817-24. PubMed ID: 19662415
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
30. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of oxaliplatin in humans.
Ehrsson H; Wallin I; Yachnin J
Med Oncol; 2002; 19(4):261-5. PubMed ID: 12512920
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
33. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
34. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
35. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands.
Momekov G; Ferdinandov D; Bakalova A; Zaharieva M; Konstantinov S; Karaivanova M
Arch Toxicol; 2006 Sep; 80(9):555-60. PubMed ID: 16485120
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.
Merkel U; Wedding U; Roskos M; Höffken K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):475-9. PubMed ID: 12877360
[TBL] [Abstract][Full Text] [Related]
37. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation.
Kawai Y; Taniuchi S; Okahara S; Nakamura M; Gemba M
Biol Pharm Bull; 2005 Aug; 28(8):1385-8. PubMed ID: 16079479
[TBL] [Abstract][Full Text] [Related]
38. Chronotoxicity of nedaplatin in rats.
Cui Y; Sugimoto K; Kawai Y; Sudoh T; Gemba M; Fujimura A
Chronobiol Int; 2004 Jul; 21(4-5):601-11. PubMed ID: 15470957
[TBL] [Abstract][Full Text] [Related]
39. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
[TBL] [Abstract][Full Text] [Related]
40. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]